trending Market Intelligence /marketintelligence/en/news-insights/trending/h2ame1pxhtlb84e_auhogg2 content esgSubNav
In This List

Actinium to raise $32.5M via sale of common shares

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Actinium to raise $32.5M via sale of common shares

Actinium Pharmaceuticals Inc. will sell up to $32.5 million worth of its common shares to Lincoln Park Capital Fund LLC.

Lincoln Park plans to initially purchase 3,376,554 common shares priced at 74 cents apiece, for a total of $2.5 million in gross proceeds for the biotechnology company. Lincoln Park can then purchase additional shares up to $30 million in multiple installments over a period of 30 months. Upon entering the agreement, Actinium issued 852,537 common shares to Lincoln Park without any cash consideration.

Actinium, a New York-based developer of cancer therapies, plans to use the proceeds for general corporate purposes, general working capital and expanding its products.